Following trastuzumab, other HER2-targeting agents including lapatinib [13], pertuzumab [14], and neratinib [15] have been approved by the US Food and Drug Administration (FDA) for the treatment of HER2+ BC. This evidence concerns the gene ERBB2 and breast cancer.